The addition of tumor antigen-specific monoclonal antibodies led to enhanced ADCC via the CD64/16A fusion protein and allowed for efficient tumor antigen targeting in ovarian cancer cell lines and in mice with ovarian cancer xenografts. This evidence concerns the gene FCGR1A and ovarian cancer.